Literature DB >> 7924895

Interaction of cefdinir with beta-lactamases.

R Labia1, A Morand.   

Abstract

The interactions of cefdinir, a new orally-active third-generation cephalosporin, with cell-free beta-lactamase preparations were studied in comparison with some other beta-lactams. Cefdinir was very resistant to narrow-spectrum Ambler's class A beta-lactamases, as it was for other oximino beta-lactams: cefotaxime, ceftazidime, cefixime and cefuroxime. Cefaclor showed a low but significant hydrolysis by these beta-lactamases. These class-A enzymes include the widespread plasmid mediated TEM-1, TEM-2, SHV-1 and also the enzymes of Gram-positive penicillinases, such as that produced by S. aureus. The hydrolysis of cefdinir was hardly detectable by the Ambler's class C beta-lactamases (cephalosporinases) produced by E. coli, E. cloacae and M. morganii. A similar conclusion is shown for cefotaxime, ceftazidime, cefixime and cefuroxime: for these beta-lactamases, the hydrolysis of cefaclor was high. The P. vulgaris cephalosporinase differs from the previous cephalosporinases in that it hydrolyses cefotaxime, cefuroxime and cefaclor efficiently. However, the hydrolysis of cefdinir remains too low to be detected. Cefdinir, as other third-generation cephalosporins, showed some hydrolysis by the novel extended-spectrum beta-lactamases (ESBL): SHV-2, TEM-3, TEM-5, MEN-1 and other ESBL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924895

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  3 in total

Review 1.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 2.  Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

Authors:  Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  GLO1 Contributes to the Drug Resistance of Escherichia coli Through Inducing PER Type of Extended-Spectrum β-Lactamases.

Authors:  He Ma; Bingjie Lai; Chunfang Zan; Xin Di; Xinran Zhu; Ke Wang
Journal:  Infect Drug Resist       Date:  2022-04-05       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.